

July 31, 2026

To,
National Stock Exchange of India Ltd.
Exchange Plaza, BKC
Bandra-Kurla Complex,
Bandra (East), Mumbai-400 051
Symbol: **JLHL**

To,
BSE Limited
P.J. Towers,
25th Floor, Dalal Street, Fort
Mumbai 400 001
Code: **543980**

Subject: Investor Presentation for the quarter ended June 30, 2026.

Reference: Unaudited Financial Results for the quarter ended June 30, 2026 (Standalone and Consolidated) of the Company.

Dear Sir/Madam,

Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended from time to time, please find the enclosed investor presentation for the Unaudited (Standalone and Consolidated) Financial Results for the quarter ended June 30, 2026.

The same will be available on the website of the Company at www.jupiterhospital.com

You are requested to kindly take the afore mentioned on record and oblige.

Thanking you,

For JUPITER LIFE LINE HOSPITALS LIMITED

Suma Upparatti
Company Secretary & Compliance Officer



CARE THAT
MOVES FORWARD,
EVERY YEAR.

Investor Presentation July 2026

This presentation and the accompanying slides (the “Presentation”), which have been prepared by **Jupiter Life Line Hospitals Limited** (the “Company”), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for any securities, and shall not form the basis or be relied on in connection with any contract or binding commitment whatsoever. No offering of securities of the Company will be made except by means of a statutory offering document containing detailed information about the Company.

This Presentation has been prepared by the Company based on information and data which the Company considers reliable, but the Company makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this Presentation. This Presentation may not be all inclusive and may not contain all of the information that you may consider material. Any liability in respect of the contents of, or any omission from, this Presentation is expressly excluded.

This presentation contains certain forward looking statements concerning the Company’s future business prospects and business profitability, which are subject to a number of risks and uncertainties and the actual results could materially differ from those in such forward looking statements. The risks and uncertainties relating to these statements include, but are not limited to, risks and uncertainties regarding fluctuations in earnings, our ability to manage growth, competition (both domestic and international), economic growth in India and abroad, ability to attract and retain highly skilled professionals, time and cost over runs on contracts, our ability to manage our international operations, government policies and actions regulations, interest and other fiscal costs generally prevailing in the economy. The Company does not undertake to make any announcement in case any of these forward looking statements become materially incorrect in future or update any forward looking statements made from time to time by or on behalf of the Company.



Dr. Ankit Thakker
MD & CEO

Patient First

“Our Dombivli hospital completed its first full quarter of operations, occupancy has been increasing steadily, supported by increasing patient footfall, expansion of clinical services and growing patient acceptance. The EBITDA loss from Dombivli of 9.5 crore in this quarter is in line with internal projections and earlier guidance. We have also initiated process of insurance empanelment, which is expected to further improve patient inflows in the coming quarters. In line with our phased development strategy, we continue to add new specialties, strengthen our consultant base and expand service offerings to support a steady ramp-up.


Pune South, Mira Road and BKC projects are continuing progress as discussed earlier.

Our established hospitals continue to maintain healthy occupancy levels, providing a stable financial and operational base.”



Q1FY27 Performance Highlights

Rs in Cr




- EBITDA impacted by initial ramp-up loss of Rs 9.5 cr in Dombivli and higher marketing costs on account of launch related activities
- Higher depreciation following commercialisation of Dombivli hospital
- Higher finance costs owing to an increase in debt for ongoing capex


Q1FY27 Operating Metrics

Operational Bed Capacity⁽¹⁾


Census Beds Non - Census Beds




Average Occupancy Rate⁽²⁾




IPD & OPD Volumes ('000)⁽³⁾




ARPOB⁽⁴⁾



ALOS (in Days)⁽⁵⁾



Payor Mix



ARPOB rounded off to the nearest hundred

1) Operational beds includes census beds (bed available for mid-night occupancy such as intensive care units ("ICUs"), wards etc.) and non-census beds (all other bed available other than census beds, such as day-care beds, casualty beds etc.) (2) Average occupancy rate is calculated as census occupied bed days (i.e. midnight census of occupied census beds during the period) divided by available census bed days (i.e. census bed capacity multiplied by the applicable days in the relevant period) (3) Out-patient volume refers to the total number of Out-patient bills generated in a specific period. Inpatient volume refers to the total number of inpatient discharge in a specific period irrespective of admission date. (4) ARPOB is calculated as income from hospital services divided by census occupied bed days (i.e. midnight census of occupied census beds during the period) (5) ALOS is the average length of stay of patients in a specific period, calculated as census occupied bed days (i.e. midnight census of occupied census beds during the period) divided by inpatient volume.

Consolidated Profit & Loss Statement

Profit and Loss (in Rs. Crs)	Q1FY27	Q1FY26	YoY	Q4FY26	QoQ	FY26
Revenue from Operations	392.6	337.9	16.2%	371.7	5.6%	1,435.6
Other Income - Operational	18.4	15.0		16.1		64.2
Total Income	411.0	352.9	16.4%	387.8	6.0%	1,499.8
Cost of Goods Sold	80.0	70.7		73.7		287.3
Gross Profit	331.0	282.2	17.3%	314.1	5.4%	1,212.5
Gross Profit Margin	80.5%	80.0%		81.0%		80.8%
Employee Cost	74.5	61.7		67.7		256.3
Professional Fees	102.2	82.7		91.6		364.0
Other Expenses	75.0	59.4		65.6		248.9
EBITDA	79.3	78.4	1.1%	89.2	-11.1%	343.3
EBITDA Margin	19.3%	22.2%		23.0%		22.9%
Depreciation	26.4	21.2		23.3		87.6
EBIT	52.9	57.2	-7.5%	65.9	-19.8%	255.6
EBIT Margin	12.9%	16.2%		17.0%		17.0%
Other Income - Finance	10.6	12.8		9.1		42.4
Finance Cost	12.9	8.3		9.0		32.7
Exceptional Item Gain / (Loss)*	0.0	0.0		1.5		-4.9
PBT	50.6	61.7	-18.1%	67.5	-25.0%	260.4
PBT Margin	12.3%	17.5%		17.4%		17.4%
Tax	13.1	17.8		17.3		66.2
PAT	37.5	43.9	-14.7%	50.2	-25.3%	194.2
PAT Margin	9.1%	12.5%		12.9%		12.9%
Basic EPS	5.72	6.69		7.66		29.59

- EBITDA includes an operational loss of Rs 9.5 cr and Rs 9.4 cr from Dombivli Hospital for Q1FY27 and Q4FY26 respectively during the initial ramp-up phase
- Depreciation has increased due to capitalisation of newly added beds
- Finance cost increased on account of debt taken for expansion projects

Next-Phase of Growth: Scaling Bed Capacity from 1,700 to 2,900

Hospitals	Bed Capacity	Capex/Bed (Excl. Land) (Rs in cr)	Remarks
-----------	--------------	--------------------------------------	---------

Recently Commissioned

Dombivli	500	1.0	Phase-wise commissioning underway, with ~200 beds operational and fit-outs completed for an additional 100 beds
----------	-----	-----	---

Greenfield

Pune II	500	1.2	Under construction
Mira - Bhayandar	300	1.3	Project currently at conceptualization and planning stage
BKC	400	1.5	Documentation & registration

Strong post IPO Expansion of 1,700 beds at an Average Cost/Bed of ~ **Rs 1.5 Cr***

Strategic Priorities Behind Expansion

- ✓ Strategic land bank in high-demand micro markets
- ✓ Phased commissioning to optimize capital deployment
- ✓ Strong operating leverage from consolidated scale

*Including land cost



Internal accruals

Cash flow to EBITDA conversion averaging **~75–80%** over the last five years is expected to support a significant portion of the planned expansion capex



Cash on hand

Cash & Cash Equivalent, including Investments of **Rs 537.7 crs**



Leverage

Targeted Debt/EBITDA is expected to remain below **3x**

Prudent Capital Deployment to Fuel Growth



Jupiter Life Line Hospitals Limited

CIN: L85100MH2002PLC137908

investor.relations@jupiterhospital.com



Strategic Growth Advisors Pvt. Ltd.

CIN: U74140MH2010PTC204285

Mandar Chavan / Rahul Agarwal
mandar.chavan@sgapl.net / rahul.agarwal@sgapl.net
+91 96993 82195 / +91 98214 38864

Thank You